PROVECTUS BIOPHARMS - PVCT STOCK NEWS

Provectus (OTCQB: PVCT) announced an exclusive worldwide license agreement with the University of Miami for a photodynamic antimicrobial therapy (PDAT) device. This collaboration will use Provectus’ rose bengal for treating bacterial, fungal, and viral infections of the eye. The company has also initiated a sponsored research program with the Ophthalmic Biophysics Center to explore rose bengal's efficacy against infectious keratitis. OBC has established its clinical proof-of-concept in treating microbial keratitis, including drug-resistant strains.

Provectus (OTCQB: PVCT) has expanded its research collaboration with Dr. Michio Kurosu at the University of Tennessee Health Science Center. This initiative focuses on evaluating pharmaceutical-grade rose bengal for its effectiveness against fungal and oral bacterial infections. The research will explore in vitro activity against various fungal strains and test susceptibility against mouth microbes. Previous studies have indicated favorable tolerability and antibacterial effectiveness of rose bengal. Provectus continues to develop immunotherapy treatments across multiple clinical areas, including oncology and dermatology.

Provectus (PVCT) announced an expansion of its sponsored research program with Dr. Aru Narendran at the University of Calgary, focusing on the treatment of pediatric leukemia using its proprietary rose bengal. The research aims to identify effective drug combinations, evaluate drug administration routes, and explore the modulation of specific pathways. Previous studies have shown promising in vitro activity of rose bengal against leukemia cells and initial in vivo effectiveness in mouse models.

Provectus (OTCQB: PVCT) has launched a new sponsored research program with Dr. Kelly Tseng from the University of Nevada, Las Vegas, aimed at studying the effects of rose bengal sodium (RBS) on vertebrate tissue regeneration. The research will utilize the African clawed frog as a model organism to evaluate key biological processes such as embryo development and wound healing. RBS is Provectus' lead compound in a class of small molecules known as halogenated xanthenes, which the company exclusively owns.

Provectus (OTCQB: PVCT) announced updated data from its Phase 1 trial targeting metastatic uveal melanoma (mUM) patients treated with the investigational immunocatalyst PV-10. Presented at the 20th Congress of the International Society of Ocular Oncology in June 2022, findings highlighted successful responses in patients receiving PV-10 injections. The study allows for multiple tumor injections per treatment cycle with assessments every three months. Provectus continues to develop various immunotherapy medicines, focusing on oncology and other disease areas.

Provectus (OTCQB: PVCT) announced on June 23, 2022, that shareholders approved a reverse stock split and an authorized share reduction during the 2022 Annual Meeting held on June 22. Other approved proposals include the election of directors and executive compensation. The Board aims to enhance shareholder value through these measures. Detailed voting results are available in Provectus' Form 8-K filed the same day. The company focuses on developing immunotherapy medicines for various diseases, particularly in oncology and dermatology.

Provectus (PVCT) announced promising results from its Phase 1 trial of PV-10 for metastatic uveal melanoma (mUM), presented at ASCO 2022. Notably, 29% of Stage IV M1a mUM patients achieved a metabolic complete response (mCR), with survival times ranging from 12.4 to over 48.8 months post-treatment. The trial utilized advanced imaging techniques like PET-CT, affirming their effectiveness in monitoring treatment response. The findings suggest that PV-10 combined with immune checkpoint blockade may enhance patient outcomes, emphasizing the need for early intervention in mUM.

Provectus (OTCQB: PVCT) announced that the USPTO has allowed its patent application 16/204,832 for a combination of topical PH-10 and systemic therapies to treat inflammatory skin conditions, including psoriasis and atopic dermatitis. This marks Provectus’ first patent award in dermatology. The patent is co-assigned with Rockefeller University, with Dr. James Krueger as co-inventor. PH-10 is a clinical-stage immunotherapy treatment. The company focuses on developing halogenated xanthene-based therapies across various medical areas, including oncology and virology.

Provectus (OTCQB: PVCT) announced that data from its ongoing clinical trial of PV-10, an investigational cancer immunotherapy, will be presented at the ASCO 2022 annual meeting from June 3-7, 2022, in Chicago. The focus is on treating metastatic uveal melanoma (mUM) to the liver. Key details include:

• Abstract Title: Metabolic complete responses in mUM patients treated with PV-10
• Abstract Number: 9543
• Session Date: June 6, 2022, 1:15-4:15 PM CDT

This presentation highlights the potential of PV-10 in oncology.